Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | Director | June 15, 2023 | June 20, 2023 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | May 29, 2026 | June 02, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 04, 2026 | June 04, 2026 |
| Tempest Therapeutics, Inc.OVAS · Entity 7734 | Director | June 13, 2017 | July 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 46,696 |
Reported balance
After 2023-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 12,922 · Balance 46,696 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.41 · Expires 2033-06-14 | Direct | 26,975 |
Reported balance
After 2023-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-15 · Grant · Acquired 26,975 · Balance 26,975 F3: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F4: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. |
| American Depositary SharesSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2023-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 30,000 F2: Each American Depositary Share represents 13 ordinary shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended.
F2: Each American Depositary Share represents 13 ordinary shares.
F3: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
F4: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.
Kiniksa Pharmaceuticals International, plc
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 15,345 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Exercise / conversion · Acquired 2,799 · Balance 15,345 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.38 · Expires 2036-05-28 | Direct | 12,158 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 12,158 · Balance 12,158 F3: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 2,026 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 2,026 · Balance 2,026 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-29 · Exercise / conversion · Disposed 2,799 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 71,967 |
Reported balance
Holding disclosure · report date 2026-05-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 71,967 F2: Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: Mr. Malley is the president of Mossrock Capital, LLC (Mossrock) and may be deemed to beneficially own the shares owned by Mossrock.
F3: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
F4: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
F5: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.
Kura Oncology, Inc.
Report date June 04, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03 | Direct | 35,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
Tempest Therapeutics, Inc.
Report date June 13, 2017 · Filed July 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 204,981 |
Reported balance
After 2017-06-13 transaction · row 1
1 source rowRow 1 · 2017-06-13 · Grant · Acquired 7,873 · Balance 204,981 F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 4, 2026 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 35,000 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001193125-26-257896 · ownership.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001403322-26-000002 · form4-06022026_080631.xml · derivative · entry 5 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. F5 · derivative.expiration_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001403322-26-000002 · form4-06022026_080631.xml · derivative · entry 4 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,026 Underlying: Class A Ordinary Shares · 2,026 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. F4 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 12,158 | $0.00 Strike: $48.38 | $0.00 |
DisclosureSEC source: 0001403322-26-000002 · form4-06022026_080631.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,158 Underlying: Class A Ordinary Shares · 12,158 shares Expires 2036-05-28 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 2,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001403322-26-000002 · form4-06022026_080631.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 13:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001193125-26-116834 · ownership.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents stock options exercised. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 13:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 10,000 | $3.12 | $31,200.00 |
DisclosureSEC source: 0001193125-26-116834 · ownership.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents stock options exercised. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 26,236 | $0.00 Strike: $15.19 | $0.00 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · derivative · entry 18 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 26,236 shares Expires 2033-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 33,237 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · derivative · entry 17 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 33,237 shares Expires 2031-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 18,760 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · derivative · entry 16 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 18,760 shares Expires 2029-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Shares | 78,233 | $33.09 | $2,588,729.97 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 10 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.82 and $33.41. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 26,236 | $15.19 | $398,524.84 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 9 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 33,237 | $14.33 | $476,286.21 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 8 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 18,760 | $15.47 | $290,217.20 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 7 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 30,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · derivative · entry 15 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 30,000 shares Expires 2032-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 20,129 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · derivative · entry 14 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 20,129 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Shares | 50,129 | $33.32 | $1,670,298.28 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 6 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.1301 and $33.50. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 30,000 | $9.88 | $296,400.00 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 5 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 20,129 | $10.36 | $208,536.44 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 4 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 27,448 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · derivative · entry 13 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 27,448 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 21,959 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · derivative · entry 12 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 21,959 shares Expires 2026-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Shares | 49,407 | $32.40 | $1,600,786.80 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.06 and $32.685. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 27,448 | $3.80 | $104,302.40 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 2 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 21,959 | $1.86 | $40,843.74 |
DisclosureSEC source: 0001415889-25-021941 · form4-08142025_080859.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015796 · form4-06052025_090659.xml · derivative · entry 5 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 3,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. F5 · derivative.expiration_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Shares | 3,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015796 · form4-06052025_090659.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 28,500 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0000950170-25-083036 · ownership.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015796 · form4-06052025_090659.xml · derivative · entry 4 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,799 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. F4 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:02 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 16,798 | $0.00 Strike: $29.11 | $0.00 |
DisclosureSEC source: 0001415889-25-015796 · form4-06052025_090659.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,798 Underlying: Class A Ordinary Shares · 16,798 shares Expires 2035-06-02 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016002 · form4-06072024_080658.xml · derivative · entry 5 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. F5 · derivative.expiration_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 4,373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-016002 · form4-06072024_080658.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016002 · form4-06072024_080658.xml · derivative · entry 4 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,173 Underlying: Class A Common Shares · 3,173 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. F4 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 19,040 | $0.00 Strike: $19.71 | $0.00 |
DisclosureSEC source: 0001415889-24-016002 · form4-06072024_080658.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,040 Underlying: Class A Common Shares · 19,040 shares Expires 2034-06-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 5, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 26,000 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0000950170-24-070698 · ownership.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010564 · form4-07032023_040714.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. F3 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-010564 · form4-07032023_040714.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:29 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon stock | 50,000 | $11.50 | $575,000.00 |
DisclosureSEC source: 0001209191-23-038797 · doc4.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Mossrock Capital, LLC Disclosed balance after: 139,557 F1 · ownership.nature: Mr. Malley serves as President of Mossrock Capital, LLC and has sole voting and investment power over these shares. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 23:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 26,975 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001651308-23-000097 · wf-form4_168730201626632.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,975 Underlying: Ordinary Shares · 26,975 shares Expires 2033-06-14 F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F4 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 23:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 12,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-23-000097 · wf-form4_168730201626632.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,696 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:23 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009430 · form4-06082023_080600.xml · derivative · entry 2 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,373 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:23 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 26,236 | $0.00 Strike: $15.19 | $0.00 |
DisclosureSEC source: 0001415889-23-009430 · form4-06082023_080600.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,236 Underlying: Class A Common Shares · 26,236 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:53 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 26,000 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0001209191-23-033859 · doc4.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007106 · form4-06302022_010614.xml · derivative · entry 2 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of grant, June 29, 2022. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 30,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001415889-22-007106 · form4-06302022_010614.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Shares · 30,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2022. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,645 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-22-000104 · wf-form4_165610662726306.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,645 Underlying: Ordinary Shares · 34,645 shares Expires 2032-06-21 F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F4 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000104 · wf-form4_165610662726306.xml · nonDerivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,774 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:46 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $14.84 | $0.00 |
DisclosureSEC source: 0001209191-22-038917 · doc4.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 33,237 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0001179110-21-007184 · edgar.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,237 Underlying: Class A Common Shares · 33,237 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 29, 2021. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 21:16 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001209191-21-042782 · doc4.xml · derivative · entry 1 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 17,498 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000121 · wf-form4_162430781053430.xml · derivative · entry 3 Malley Thomas · CIK 0001403322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Ordinary Shares · 17,498 shares Expires 2031-06-15 F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F4 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.